Overview
Truist Securities elevated its price target for Agios Pharmaceuticals to $39.00 from $38.00 and kept a Buy recommendation on the shares. The research firm’s adjustment comes in the wake of Agios’ fourth-quarter 2025 financial results and additional clarity around the company’s regulatory and commercial plans for key programs.
Market context and valuation
Analysts’ price targets for Agios span a wide range, from $25 to $62, and the consensus view included in available metrics continues to suggest the shares may be undervalued. Agios stock is trading at $28.29, having climbed roughly 27% from its 52-week low, although the shares remain down about 15.5% over the past 12 months.
Drivers behind Truist’s update
Truist pointed to several near-term developments as underpinning its revised target. The firm noted that Agios has outlined next steps after a pre-NDA meeting with the U.S. Food and Drug Administration related to mitapivat in sickle cell disease (SCD). Truist is awaiting further detail on the company’s filing strategy for mitapivat following that interaction with the regulator.
On the commercial front, Agios’ recently launched treatment Aqvesme has demonstrated early prescription momentum. The drug’s Risk Evaluation and Mitigation Strategy (REMS) program was activated in late January, and Truist expects revenue recognition for Aqvesme to commence in the second quarter of 2026.
Financials and product performance
Agios reported notable quarterly revenue growth tied to its PYRUKYND product, which climbed 86% year-over-year to $20 million for the quarter. Despite that top-line progress, the company was not profitable over the last twelve months, recording a diluted loss per share of -$6.96. Financial health metrics available show an overall score labeled as "GOOD" at 2.58.
Pipeline and market opportunity
Truist remains constructive on the prospects for mitapivat, including the possibility of approval via an accelerated regulatory pathway, and is tracking commercial execution for Aqvesme closely. The research firm also cited continued attention to tebapivat and other candidates in Agios’ pipeline. Truist estimates the addressable opportunity in rare hematology at more than $10 billion, and that potential underlies its favorable view of the company.
Key points
- Truist raised Agios’ price target to $39 from $38 and kept a Buy rating, citing regulatory and commercial developments - impacts healthcare and biotech sectors.
- Analyst targets range from $25 to $62; shares trade at $28.29, up 27% from the 52-week low but down 15.5% year-over-year - relevant to equity markets and investor sentiment.
- Q4 2025 results showed PYRUKYND revenue of $20 million, an 86% year-over-year increase; Aqvesme REMS activated and revenue recognition expected in Q2 2026 - affects company revenue outlook and commercial execution assessments.
Risks and uncertainties
- Regulatory risk: Outcomes related to mitapivat’s filing strategy and potential accelerated approval remain pending and could materially affect clinical and commercial timelines - relevant to biotech and pharmaceutical investors.
- Profitability and cash-flow risk: Agios reported a diluted EPS of -$6.96 over the last twelve months and is not yet profitable, which presents balance sheet and funding considerations for the company and its peers in the sector.
- Commercial execution risk: Early prescription momentum for Aqvesme is promising, but full revenue realization depends on successful commercialization after REMS activation and continued market uptake - impacts revenue forecasts in rare hematology.
Conclusion
Truist’s modest increase in the price target and reaffirmation of a Buy rating reflect a combination of stronger recent product revenue, progress on regulatory interactions for late-stage assets, and initial commercial signs for a newly launched product. Investors and market participants will be watching forthcoming details on mitapivat’s filing approach and the pace of Aqvesme’s revenue recognition in the coming quarters.